PWM
STML

Paulson Wealth Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Paulson Wealth Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300
Closed -$5K – 584
2017
Q4 		$5K Buy
+300
New +$4.01K ﹤0.01% 454

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Paulson Wealth Management's STML Position: Q1 2018 in Review

Paulson Wealth Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2018, closing a stake of 300 shares — an estimated $5K sold.

Paulson Wealth Management first reported a position in STML in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 82 funds tracked by Wall St. Rank hold STML as of Q1 2018.

  • Paulson Wealth Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Paulson Wealth Management sold 300 Stemline Therapeutics, Inc. shares in Q1 2018, an estimated $5K.
  • Paulson Wealth Management first reported a position in Stemline Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Paulson Wealth Management's Stemline Therapeutics, Inc. position peaked at $5K in Q4 2017.
  • 82 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2018.

Based on Paulson Wealth Management's 13F filing for Q1 2018, filed 2 May 2018.